News

September 15 2022

In Memoriam: James Lloyd Hoehn, MD, FACS

September 15 2022

Protocol Committee Support (PSC) Column: No Surprises Billing Act 2022

September 15 2022

NRG Health Equity Fellowship Call for Applications

September 15 2022

Comparing the Addition of Radiation before or After Surgery for Patients with Brain Metastases (NRG-BN012)

September 15 2022

Comparing Every Three Week Versus Weekly Cisplatin with Radiotherapy for Locoregionally Advanced Squamous Cell Carcinoma of the Head and Neck (NRG-HN009)

September 15 2022

NRG-GU011 (“NRG PROMETHEAN”) study of SABR with or without relugolix for PET-recurrent oligometastatic prostate cancer

September 15 2022

NRG-GU009 ( “PREDICT-RT”) Parallel Phase III Randomized Trials For High Risk Prostate Cancer Evaluating De-Intensification For Lower Genomic Risk and Intensification of Concurrent Therapy for Higher Genomic Risk with Radiation

September 15 2022

Testing the addition of trastuzumab or trastuzumab/pertuzumab to the usual chemotherapy for HER2 positive uterine serous or carcinosarcoma (NRG-GY026)

September 12 2022

NRG Oncology accepting applications for the position of Vice Chair, Ancillary Projects Committee

August 18 2022

NRG Oncology and The GOG Foundation Honor the Life of Mary "Dicey" Scroggins

August 12 2022

Summer Meeting 2022 Protocol Support Committee (PSC) Wrap Up

August 12 2022

FORTE Study Updates: Natural Language Processing Update

August 05 2022

NRG Oncology accepting applications for the position of Vice Chair, Radiation Oncology Committee

July 29 2022

NRG Oncology Trial Aimed to Improve Prostate Cancer Survivor Care Planning Reaches Accrual Goal

July 27 2022

Oncology Tube Conducts Interviews on NRG Oncology Research Presented During the 2022 ASCO Annual Meeting: NRG-HN002 and NRG-GI008

July 26 2022

NRG Oncology NCORP Trial of Hippocampal Avoidance for Small Cell Lung Cancer Patients Receiving Prophylactic Cranial Irradiation Reaches Accrual Goal

July 19 2022

NRG Oncology Appoints Several New Committee Chairs & Vice Chairs

July 13 2022

Adding Stereotactic Radiation Therapy to Immune Therapy for Patients with Advanced Renal Cell Cancer (NRG-GU012, The “SAMURAI” Study)

July 13 2022

IACRN: International Association of Clinical Research Nurses

July 13 2022

NRG NCORP Selects CCDR Pilot Project Awardee

July 13 2022

Join FORTE at the NRG Oncology Semiannual Meeting!

July 12 2022

NRG Oncology Accepting Applications for Radiation Oncology Committee Chair Position

July 08 2022

NRG Oncology Study of Atezolizumab and Chemoradiation for Patients with Limited-Stage Small Cell Lung Cancer Completes Accrual

June 29 2022

PSA-Based Endpoints Should Not Be Used as Surrogate Endpoints for Overall Survival in Men with Recurrent Prostate Cancer at this Time

June 28 2022

Joint Final Report of Phase III trials Demonstrate Positive Outcomes from Combination of PCV Chemotherapy and RT in Patients with Anaplastic Oligodendroglial Tumors

June 27 2022

Additional Taxane Maintenance Therapy Does Not Successfully Improve Overall Survival for Women with Advanced Ovarian, Peritoneal, and Tubal Cancers

June 08 2022

The Vision of Remote Auditing and Monitoring

June 08 2022

NRG-CC005 (FORTE) Breaking News! Welcome to the FORTE Education and Communication Specialist

May 12 2022

NRG Oncology NCORP Accepting Applications for NRG Meeting Travel Awards: Deadline May 26, 2022

May 11 2022

Preparing for the NRG Quality Assurance Audit

May 11 2022

FORTE STUDY UPDATE: NRG-CC005/FORTE Trial Communications

May 11 2022

A Randomized Phase II Trial of Immunotherapy with Dual Immune Checkpoint Inhibitors Compared to Anti-PD1 Monotherapy in Patients with Deficient Mismatch Repair System Recurrent Endometrial Carcinoma (NRG-GY025)

May 11 2022

A Study Champion Perspective: Christina Henson, MD

May 11 2022

Upcoming Trial Highlight: Studying Stereotactic Radiosurgery Before Versus After Surgery for Patients with Resectable Brain Metastases (NRG-BN012)

May 11 2022

NRG-BN011 Seeks to Improve Treatment Outcomes in a Substantial Subset of Glioblastoma Patients with Dual Alkylating Therapy

May 11 2022

A Safety Run-in and Phase II Study Evaluating the Efficacy, Safety, and Impact on the Tumor Microenvironment of the Combination of Tocilizumab, Atezolizumab, and Fractionated Stereotactic Radiotherapy in Recurrent Glioblastoma (NRG-BN010)

May 09 2022

NRG Oncology Study of Photon Versus Proton Therapy for Patients with Newly Diagnosed Glioblastoma Completes Accrual

May 09 2022

NRG Oncology Board of Directors Member, Dr. Priya Rastogi named NSABP Foundation CEO

April 29 2022

NRG Oncology Executive Director is Stepping Down from the Position

April 29 2022

NRG NCORP is Soliciting PILOT Projects Focused on Biospecimens and Clinical Trial Data: Breast Cancer Prevention Studies

April 29 2022

DEADLINE APRIL 29TH: NRG Oncology seeks to fill the position of Chair, NRG Oncology Surgical Oncology Committee

April 19 2022

West Valley Ovarian Cancer Alliance Gifts Generous Donation to the NRG Oncology Under-Represented Minority Investigator Program

April 13 2022

DEADLINE EXTENDED: NRG Oncology seeks to fill the position of Chair, NRG Oncology Immunotherapy Subcommittee

April 12 2022

FORTE STUDY UPDATE: NRG-CC005 (The FORTE Study)

April 12 2022

Testing ctDNA as a Biomarker for Adjuvant Therapy Intensity in Stage 3 Colon Cancer (NRG-GI008, The “CIRCULATE-US” Study)

April 12 2022

April is National Cancer Control Month: NRG Protocol Support Committee Column

April 12 2022

Exploring Options to Potentially Improve Treatment and Quality of Life for Patients in Two Head and Neck Cancer Trials

April 11 2022

NRG Oncology Announces New Veterans Affairs and Military Treatment Facility Subcommittee, Appoints Subcommittee Chairs

April 08 2022

NRG Oncology seeks applications for Chair of the NRG Early Career New Investigators Committee

March 24 2022

Webinar: Implementation Science for Digital Health

March 18 2022

NRG Oncology Trial Indicates Using Atezolizumab with Chemoradiation is Safe and Demonstrates Signs of Immune Activation in Women with Cervical Cancer

March 18 2022

HRR Mutational Status Prognostic of Survival Outcomes in Biomarker Analysis of NRG Oncology Trial for Women with Recurrent Platinum-Sensitive Ovarian Cancer

March 16 2022

OlympiA Trial (NSABP B-55): Olaparib as adjuvant treatment reduces risk of death by 32% in patients with germline BRCA mutations and high-risk early breast cancer

March 10 2022

NRG Oncology seeks to fill the position of Co-Chair, Patient Centered Outcomes Research Committee

March 08 2022

NRG Oncology PSC 2022 Winter Meeting Wrap Up

March 08 2022

Congratulations to the NRG Oncology Members Assigned to NCI Gastrointestinal Task Forces - Rectal/Anal Cancers

March 08 2022

FORTE Study Update - March NRG Newsletter

March 08 2022

Coming Attractions or Recent Additions in NRG Colorectal Cancer Research: NRG-GI005

March 08 2022

Coming Attractions or Recent Additions in NRG Colorectal Cancer Research: NRG-GI008

March 08 2022

The NRG-GI004/SWOG1610, the COMMIT Study, may further improve outcomes in Metastatic Colorectal Cancer with deficiency of DNA repair (dMMR/MSI- H)

March 08 2022

Project Team Member Application - CBX-12

February 18 2022

NRG NCORP Solicits PILOT Projects for NRG NCORP Cancer Care Delivery Research (CCDR) Priorities

February 18 2022

NRG NCORP Solicits PILOT Projects for NRG NCORP Health Disparities Research (HDR) Priorities

February 18 2022

NRG NCORP Solicits PILOT Projects for NRG NCORP Cancer Prevention Control (CPC) Priorities

February 15 2022

2022 Symposium & Workshop: Precision Medicine Applications in Radiation Oncology

February 11 2022

The Scientific Session - February 2022

February 09 2022

NRG Oncology Announces First Participant Enrolled on FORTE NRG-CC005

February 08 2022

Dr. Miller Re-elected as Biostatistician for the NCI Uterine Task Force

February 08 2022

RECIST 1.1 Criteria Toolkit: A Resource for Success in Clinical Trials with Solid Tumor Evaluation Requirements

February 08 2022

NRG-CC008: A Non-Randomized Prospective Clinical Trial Comparing the Non-Inferiority of Salpingectomy to Salpingo-Oophorectomy to Reduce the Risk of Ovarian Cancer Among BRCA1 Carriers [SOROCk]

February 08 2022

FORTE Study Updates (Feb 2022 Newsletter)

February 03 2022

NRG Oncology Trial Results Indicate Trametinib Should Represent the New Standard of Care for Women with Recurrent Low-Grade Serous Ovarian Cancer

January 21 2022

Trastuzumab with Chemoradiation and Surgery Does Not Improve Outcomes for Esophageal Cancer Patients, Trial Highlights Future Research Opportunities

January 12 2022

It’s All in the DETAILS!

January 12 2022

Moving Research Forward through Legislative Advocacy

January 12 2022

De-intensification and Intensification Treatments for High-Risk Prostate Cancer Patients Stratified by Genomic Risk (NRG-GU009, the “PREDICT-RT” Trial)

January 12 2022

Phase 2 Double-Blinded Trial Combining Oligometastatic Radiotherapy with Androgen Deprivation Therapy (NRG-GU011)

January 12 2022

NRG-CC005 “FORTE” Amendment #3 is Now Active

January 12 2022

A Message from the Chairs of NRG Oncology’s Research Strategy Committee, 2021: The Year in Review

January 12 2022

Anti PD-L1 (Atezolizumab) as an Immune Primer and Concurrently with Extended Field Chemoradiotherapy for Node Positive Locally Advanced Cervical Cancer – Outcomes Presented Soon! (NRG-GY017)

January 11 2022

NRG Oncology Trial Data Concludes Paclitaxel and Carboplatin Should be Considered the Standard of Care as First-line Treatment for Women with Uterine Carcinosarcoma

December 20 2021

Barbara Good, PhD, to Retire from NRG Oncology and the NSABP Foundation

December 10 2021

Bupropion Does Not Improve Sexual Desire for Female Cancer Survivors on NRG Oncology Clinical Study

December 09 2021

Get to Know the Protocol Support Committee (PSC)

December 09 2021

Why Should We Participate in NRG-CC005/FORTE?

December 09 2021

Phase 3 Trial Combining Two Alkylating Agents with Radiotherapy for Newly Diagnosed Glioblastoma (NRG-BN011)

December 09 2021

Phase 3, Node-Positive Prostate Cancer Trial Reactivates Following Change to Experimental Treatment Arm (NRG-GU008, the INNOVATE trial)

December 06 2021

Winter 2021 Holiday Hours

December 01 2021

NRG Oncology Non-Small Cell Lung Cancer Trial Completed Accrual to Phase 2, Undergoing Data Analysis to Determine Reopening for Phase 3

December 01 2021

Annual Call for NRG Oncology Administrative Committee Member Applications

November 23 2021

Machtay Young Investigator Travel Award (Winter 2022 NRG Meeting)

November 16 2021

NRG Oncology Seeks Applicants for the Veterans Affairs/Military Treatment Facility Subcommittee Chair Position

November 11 2021

Mei-Yin C. Polley, PhD Re-elected to Serve as the Biostatistician on the NCI Head & Neck Steering Committee

November 11 2021

Background: National Coverage Analysis

November 11 2021

The NRG-CC005 (FORTE) Trial has Activated!

November 11 2021

Comparing High- and Low-Dose Cisplatin for Patients with Locoregionally Advanced Squamous Cell Carcinoma of the Head and Neck (NRG-HN009)

November 11 2021

New Prostate Cancer Study Testing Higher-intensity Treatment for Patients with Higher Gene Risk Scores and Lower-intensity Treatment for Patients with Lower Gene Risk Scores (NRG-GU010, the GUIDANCE trial)

November 11 2021

The University of Michigan T32 in Cancer Care Delivery Accepts First Cohort of Pre- and Post- Doctoral Scholars

November 11 2021

Congratulations to the NRG Oncology Members Assigned to NCI Gastrointestinal Task Forces

November 11 2021

Congratulations to the NRG Oncology Members Assigned to NCI Gastrointestinal Task Forces

November 11 2021

Combining Radiotherapy and Immunotherapy in Patients with Extensive Stage Small Cell Lung Cancer (NRG-LU007, “the RAPTOR Trial”)

October 25 2021

Hypofractionated Post-Operative Prostate Bed Radiotherapy Does Not Increase Patient-Reported Toxicity for Men with Prostate Cancer

October 25 2021

Total Androgen Suppression with Dose-Escalated Radiotherapy Does Not Improve Overall Survival in Men with Intermediate-Risk Prostate Cancer: Results Highlight Need for Biomarker Studies

October 14 2021

HEAL Initiative: Advancing Health Equity in Pain Management - NOTIFY NRG BY 10/31/21

October 12 2021

Amendment to address accrual barriers for NRG-BR004 is activated

October 12 2021

Remote Audits – What is working and what is still missing

October 12 2021

Former Gynecologic Oncology Group Co-Chair, Dr. Franco Muggia, dies at 85

October 12 2021

NCI-Sponsored Trials Have Added 14-Million Years of Life for Cancer Patients

October 12 2021

Congratulations to the NRG Oncology NCORP Members Assigned to NCI Steering Committees

October 12 2021

Stewart Anderson retires from University of Pittsburgh

October 12 2021

Jim Dignam Receives the SPAIG Award

October 12 2021

Assessing the Maximum-Tolerated Dose of AMG 232 (KRT-232) with Concurrent Radiotherapy in the Treatment of Soft Tissue Sarcoma with Wild-Type P53 Gene (NRG-DT001)

October 12 2021

Congratulations to the NRG Oncology Members Assigned to NCI Gastrointestinal Task Forces

October 07 2021

NSABP and RTOG Foundations Join GOG Foundation in Funding of the NRG Oncology Health Equity New Investigator Mentor Program

October 06 2021

NRG Oncology Launches FORTE, a Colorectal Cancer Prevention Clinical Trial

September 27 2021

Breast Radiation following Lumpectomy Confirmed to Reduce Incidence of IBR for “Good Risk” DCIS

September 14 2021

Getting Started with Radiation Therapy (RT) Credentialing (September 2021 Newsletter)

September 14 2021

NRG-CC005 (FORTE): Five- or Ten-Year Colonoscopy for 1-2 Non-Advanced Adenomatous Polyps (September 2021 Newsletter)

September 14 2021

NRG Oncology Health Equity New Investigator Mentor Program for Underrepresented Minority (URM) Scholars (September 2021 Newsletter)

September 14 2021

OvCa Survivors and Thrivers Make Remarkable Strides in Research (Sept 2021 Newsletter)

September 14 2021

Highlighting NRG Gynecologic Studies: Gynecologic Cancer Awareness Month (Sept 2021 Newsletter)

August 27 2021

NRG Oncology Appoints Dr. Sue Yom as New Head and Neck Cancer Committee Chair

August 24 2021

Survival Benefits Not Seen with Addition of Metformin to Concurrent Chemoradiation in Patients with Locally Advanced Non-Small Cell Lung Cancer

August 13 2021

NRG Oncology Limited-Stage Small Cell Lung Cancer Trial Participant Interviewed on his Journey

August 13 2021

Opinion: Adoption of Clinical Research Competencies can Set the Stage for Research Success

August 13 2021

Assessing the Maximum-Tolerated Dose and the Efficacy of Tocilizumab and Atezolizumab in the Treatment of Recurrent Glioblastoma (NRG-BN010)

August 13 2021

Testing Durvalumab, Olaparib, and Cediranib in Women with Platinum-Resistant Recurrent Epithelial Ovarian Cancer, Primary Peritoneal, or Fallopian Tube Cancer (NRG-GY023)

August 13 2021

NRG Oncology Director of Administration, Meetings, and Exhibits, Denise Mackey, Retires After 38 Years

August 13 2021

Outstanding NRG Oncology Researcher to Receive 2021 PA Breast Cancer Coalition Potamkin Prize

August 13 2021

NRG Oncology Board of Directors Member, Dr. Jeff Michalski, Named ASTRO President-elect

July 22 2021

NRG Oncology Plenary Session with Keynote Speaker Dr. Philip E. Castle

July 13 2021

Pathology and Biospecimen Tips for Success

June 28 2021

Quynh Le, MD Appointed as an NRG Oncology Group Chair

We are pleased to announce that Quynh-Thu Le, MD, from Stanford University, will serve as one of our three Group Chairs effective July 1, 2021. Read more

June 16 2021

Navigating the Virtual NRG Oncology Group Meeting

June 16 2021

NRG Oncology GI Committee members appointees to NCI Task Forces

June 16 2021

Investigating Deintensification of Head and Neck Radiation within NRG Oncology

June 16 2021

FORTE Coming Soon!

Five- or Ten-Year Colonoscopy for 1-2 Non-Advanced Adenomatous Polyps Read more

June 16 2021

Recently Activated! NRG-BR007: The DEBRA Trial

Testing Hormonal Therapy Following Lumpectomy without Radiotherapy for Patients with Low-Risk, Early-Stage Breast Cancer (NRG-BR007: The DEBRA Trial) Read more

June 03 2021

OlympiA study results to be presented at 2021 ASCO Annual Meeting

May 12 2021

Performance Status Measures - A Little History

April 22 2021

NRG Oncology Study Shows Safety of Using Stereotactic Body Radiotherapy to Treat Multiple Metastases

April 14 2021

Esophageal Cancer Awareness Month

April 14 2021

Head and Neck Cancer Awareness Month

April 14 2021

Acupuncture in Oncology

March 09 2021

The Significance of Checkpoint Inhibitors and MMR/MSI Testing in Metastatic Colorectal Cancer (NRG-GI004/SWOG1610, the COMMIT Study)

March 09 2021

Implementing Remote Consenting at the University of Hawaii Cancer Center, A Minority/Underserved NCORP Site

March 09 2021

Comparing Hippocampal-Avoidant Whole Brain Radiotherapy to Stereotactic Radiosurgery for Patients with 10 or Fewer Brain Metastases from Small Cell Lung Cancer (NRG-CC009)

March 09 2021

NRG Oncology Board of Directors Appoints New At-Large Director

February 26 2021

NRG NCORP Solicits PILOT Projects for Applications: Biospecimens & Clinical Trial Data from Breast Cancer Prevention Studies

February 23 2021

NRG Cancer Prevention Committee Seeks Applications for Chair of Committee

February 19 2021

NSABP B-55/BIG 6-13 / OlympiA trial crossed superiority boundary for invasive disease-free survival vs. placebo at planned interim analysis

February 19 2021

NRG Oncology NCORP solicits PILOT projects addressing NRG NCORP Health Disparities (HDC) Research priorities

February 19 2021

NRG Oncology NCORP is soliciting PILOT projects for applications focused on NRG NCORP Cancer Prevention and Control (CPC) priorities

February 19 2021

NRG Oncology NCORP solicits PILOT projects addressing NRG NCORP Cancer Care Delivery Research (CCDR) priorities

February 18 2021

NRG Oncology’s Practice Changing Study on HA-WBRT plus Memantine Was Among Journal of Clinical Oncology’s Top 5 Downloads in 2020

February 12 2021

The First Lady of the United States and NCI Leadership Highlight the Importance of NCORP on World Cancer Day

February 11 2021

Recipe for Success for Quality of Life Questionnaire Study Compliance

February 11 2021

NRG-CC008 Trial Now Open - February 2021 Newsletter

February 11 2021

National Cancer Prevention Month - February 2021 Newsletter

February 02 2021

NRG Oncology Appoints New Committee Chairs for Pathology and Health Disparities Research

January 29 2021

The General Session at the NRG Winter 2021 Virtual Meeting

January 29 2021

NRG NCORP Townhall at the NRG Winter 2021 Virtual Meeting

January 29 2021

Reduced-Dose Radiation with Cisplatin Improves Outcomes for HPV-associated Oropharyngeal Carcinoma Patients on NRG Oncology Study, Justifies Phase III Trial

January 29 2021

NRG Oncology Trial Results Show Safety of Adaptive Radiotherapy in Non-Small Cell Lung Cancer Patients, Open Paths to Future Prospective Studies

January 28 2021

The NRG New Investigator Sessions at the NRG Winter 2021 Virtual Meeting

January 20 2021

NRG Oncology Health Equity New Investigator Mentor Program for Underrepresented Minority Scholars

January 19 2021

A Message from Drs. Norman Wolmark and Robert Mannel

January 16 2021

NRG Oncology Study Determines Total Neoadjuvant Therapy with Pembrolizumab and Chemoradiotherapy is Safe, but May Not be Beneficial for Patients with Locally-Advanced Rectal Cancer

January 12 2021

Keeping a Positive Attitude as a Cancer Research Nurse, Through a Global Pandemic

January 12 2021

De-intensification and Intensification Treatments for High-Risk Prostate Cancer Patients Stratified by Genomic Risk (NRG-GU009)

January 12 2021

Does the Addition of Hippocampal-Avoidant Whole Brain Radiotherapy and Memantine to Salvage Radiosurgery Prevent Neurologic Death for Patients with Recurrent Brain Metastases and High Brain Metastasis Velocity after Upfront Radiosurgery? (NRG-BN009)

January 12 2021

2020 In Review: A Message from the Chairs of NRG Oncology’s Research Strategy Committee

January 12 2021

NRG Oncology Elects Two Members to its Board of Directors

December 15 2020

Updated Message from NRG Oncology Leadership on COVID-19

December 14 2020

NRG Oncology Winter Holiday Hours

December 11 2020

Adding Peposertib to Radiotherapy for Patients with Advanced Head and Neck Cancer Who are Cisplatin-Ineligible (NRG-HN008)

November 10 2020

Unique Trial Combines Concurrent Immunotherapy and Radiation Therapy to Determine if this Treatment Option Improves Survival Outcomes for Patients with Limited-Stage Small Cell Lung Cancer (NRG-LU005)

October 28 2020

Follow Up Results on First Multicenter Trial to Report Outcomes of Salvage Low Dose Radiotherapy Brachytherapy after External Beam Radiotherapy for Prostate Cancer

October 28 2020

NRG-RTOG 0617 Validates ERCC1/2 Genotypic Signature as a Radiosensitivity Biomarker for Tumor and Normal Tissues in Non-Small Cell Lung Cancer Patients

October 28 2020

NRG Oncology Study on Treatment for Advanced Endometrial Cancer Chosen as ‘Editor’s Choice’ in Journal of Clinical Oncology

October 27 2020

Updated Analysis of NRG-RTOG 9813 Indicates IDH1/2 Mutation Status is Statistically Associated with Better Overall and Progression-free Survival for Patients with Anaplastic Astrocytoma

October 26 2020

Metastasis-Free Survival is a Strong Surrogate Endpoint for Overall Survival over Biochemical Failure for Men Receiving Salvage Radiotherapy for Recurrent Prostate Cancer

October 26 2020

PILOT Grant Announcement for NRG NCORP Health Disparities Research

October 26 2020

PILOT Grant Announcement for NRG NCORP Cancer Care Delivery Research

October 26 2020

PILOT Grant Announcement for NRG NCORP Cancer Prevention and Control

October 25 2020

Updated Results of NRG Oncology Trial Display Effectiveness of Gemcitabine and Daily Radiation for Bladder Preservation in Muscle-Invasive Bladder Cancer Patients

October 24 2020

NRG-BN001 Photon IMRT Treatment Group Displays No Significant Survival Difference Between Arms for Patients with Glioblastoma, Proton Treatment Group Still Accruing

October 12 2020

Exploring the Addition of Nivolumab to Platinum-Gemcitabine for Recurrent or Metastatic Nasopharyngeal Cancer (NRG-HN007)

October 12 2020

Breast Cancer Awareness Month: Why it Matters

September 29 2020

NCI Proton Letter for NRG Sites to Send to Patients' Insurance Carrier

September 14 2020

NRG Oncology Health Disparities Committee (HDC) Update (9/14/2020)

September 14 2020

Can Immunotherapy Improve Outcomes for Patients with MGMT Unmethylated Glioblastoma on NRG-BN007?

September 14 2020

The Raptor Trial (NRG-LU007) for Extensive Stage Small Cell Lung Cancer

September 14 2020

A New Trial in Localized High Risk Prostate Cancer (GU009) is Opening Soon!

September 14 2020

Randomized phase III trial of radiation therapy with or without pembrolizumab for women with high intermediate risk mismatch repair deficient (dMMR) endometrioid endometrial cancer (NRG-GY020)

August 28 2020

Genomic Analysis Predicts Survival Benefit of Adjuvant Chemotherapy Following Radiotherapy over Radiotherapy Alone in Low-Grade Gliomas in NRG Oncology Clinical Trial

Genomic Analysis Predicts Survival Benefit of Adjuvant Chemotherapy Following Radiotherapy over Radiotherapy Alone in Low-Grade Gliomas in NRG Oncology Clinical Trial Read more

August 20 2020

Calling all NRG Oncology Investigators! NRG-GY022 is open for ANY cancer patient undergoing carboplatin treatment, any cycle!

August 07 2020

Dr. Bauman named Co-Chair of the NCI Cancer Prevention Steering Committee

August 07 2020

NRG Oncology Trial Compares Sentinel Lymph Node Biopsy to Standard Neck Dissection for patients with Early-stage Oral Cavity Cancer

August 07 2020

The NRG Oncology SOROCk Trial Compares Two Surgical Procedures in Women with BRCA1 Mutations to Assess Risk Reduction for Ovarian Cancer

All News

In Memoriam: James Lloyd Hoehn, MD, FACS

Protocol Committee Support (PSC) Column: No Surprises Billing Act 2022

NRG Health Equity Fellowship Call for Applications

Comparing the Addition of Radiation before or After Surgery for Patients with Brain Metastases (NRG-BN012)

Comparing Every Three Week Versus Weekly Cisplatin with Radiotherapy for Locoregionally Advanced Squamous Cell Carcinoma of the Head and Neck (NRG-HN009)

NRG-GU011 (“NRG PROMETHEAN”) study of SABR with or without relugolix for PET-recurrent oligometastatic prostate cancer

NRG-GU009 ( “PREDICT-RT”) Parallel Phase III Randomized Trials For High Risk Prostate Cancer Evaluating De-Intensification For Lower Genomic Risk and Intensification of Concurrent Therapy for Higher Genomic Risk with Radiation

Testing the addition of trastuzumab or trastuzumab/pertuzumab to the usual chemotherapy for HER2 positive uterine serous or carcinosarcoma (NRG-GY026)

NRG Oncology accepting applications for the position of Vice Chair, Ancillary Projects Committee

NRG Oncology and The GOG Foundation Honor the Life of Mary "Dicey" Scroggins

Summer Meeting 2022 Protocol Support Committee (PSC) Wrap Up

FORTE Study Updates: Natural Language Processing Update

NRG Oncology accepting applications for the position of Vice Chair, Radiation Oncology Committee

NRG Oncology Trial Aimed to Improve Prostate Cancer Survivor Care Planning Reaches Accrual Goal

Oncology Tube Conducts Interviews on NRG Oncology Research Presented During the 2022 ASCO Annual Meeting: NRG-HN002 and NRG-GI008

NRG Oncology NCORP Trial of Hippocampal Avoidance for Small Cell Lung Cancer Patients Receiving Prophylactic Cranial Irradiation Reaches Accrual Goal

NRG Oncology Appoints Several New Committee Chairs & Vice Chairs

Adding Stereotactic Radiation Therapy to Immune Therapy for Patients with Advanced Renal Cell Cancer (NRG-GU012, The “SAMURAI” Study)

IACRN: International Association of Clinical Research Nurses

NRG NCORP Selects CCDR Pilot Project Awardee

Join FORTE at the NRG Oncology Semiannual Meeting!

NRG Oncology Accepting Applications for Radiation Oncology Committee Chair Position

NRG Oncology Study of Atezolizumab and Chemoradiation for Patients with Limited-Stage Small Cell Lung Cancer Completes Accrual

PSA-Based Endpoints Should Not Be Used as Surrogate Endpoints for Overall Survival in Men with Recurrent Prostate Cancer at this Time

Joint Final Report of Phase III trials Demonstrate Positive Outcomes from Combination of PCV Chemotherapy and RT in Patients with Anaplastic Oligodendroglial Tumors

Additional Taxane Maintenance Therapy Does Not Successfully Improve Overall Survival for Women with Advanced Ovarian, Peritoneal, and Tubal Cancers

The Vision of Remote Auditing and Monitoring

NRG-CC005 (FORTE) Breaking News! Welcome to the FORTE Education and Communication Specialist

NRG Oncology NCORP Accepting Applications for NRG Meeting Travel Awards: Deadline May 26, 2022

Preparing for the NRG Quality Assurance Audit

FORTE STUDY UPDATE: NRG-CC005/FORTE Trial Communications

A Randomized Phase II Trial of Immunotherapy with Dual Immune Checkpoint Inhibitors Compared to Anti-PD1 Monotherapy in Patients with Deficient Mismatch Repair System Recurrent Endometrial Carcinoma (NRG-GY025)

A Study Champion Perspective: Christina Henson, MD

Upcoming Trial Highlight: Studying Stereotactic Radiosurgery Before Versus After Surgery for Patients with Resectable Brain Metastases (NRG-BN012)

NRG-BN011 Seeks to Improve Treatment Outcomes in a Substantial Subset of Glioblastoma Patients with Dual Alkylating Therapy

A Safety Run-in and Phase II Study Evaluating the Efficacy, Safety, and Impact on the Tumor Microenvironment of the Combination of Tocilizumab, Atezolizumab, and Fractionated Stereotactic Radiotherapy in Recurrent Glioblastoma (NRG-BN010)

NRG Oncology Study of Photon Versus Proton Therapy for Patients with Newly Diagnosed Glioblastoma Completes Accrual

NRG Oncology Board of Directors Member, Dr. Priya Rastogi named NSABP Foundation CEO

NRG Oncology Executive Director is Stepping Down from the Position

NRG NCORP is Soliciting PILOT Projects Focused on Biospecimens and Clinical Trial Data: Breast Cancer Prevention Studies

DEADLINE APRIL 29TH: NRG Oncology seeks to fill the position of Chair, NRG Oncology Surgical Oncology Committee

West Valley Ovarian Cancer Alliance Gifts Generous Donation to the NRG Oncology Under-Represented Minority Investigator Program

DEADLINE EXTENDED: NRG Oncology seeks to fill the position of Chair, NRG Oncology Immunotherapy Subcommittee

FORTE STUDY UPDATE: NRG-CC005 (The FORTE Study)

Testing ctDNA as a Biomarker for Adjuvant Therapy Intensity in Stage 3 Colon Cancer (NRG-GI008, The “CIRCULATE-US” Study)

April is National Cancer Control Month: NRG Protocol Support Committee Column

Exploring Options to Potentially Improve Treatment and Quality of Life for Patients in Two Head and Neck Cancer Trials

NRG Oncology Announces New Veterans Affairs and Military Treatment Facility Subcommittee, Appoints Subcommittee Chairs

NRG Oncology seeks applications for Chair of the NRG Early Career New Investigators Committee

Webinar: Implementation Science for Digital Health

NRG Oncology Trial Indicates Using Atezolizumab with Chemoradiation is Safe and Demonstrates Signs of Immune Activation in Women with Cervical Cancer

HRR Mutational Status Prognostic of Survival Outcomes in Biomarker Analysis of NRG Oncology Trial for Women with Recurrent Platinum-Sensitive Ovarian Cancer

OlympiA Trial (NSABP B-55): Olaparib as adjuvant treatment reduces risk of death by 32% in patients with germline BRCA mutations and high-risk early breast cancer

NRG Oncology seeks to fill the position of Co-Chair, Patient Centered Outcomes Research Committee

NRG Oncology PSC 2022 Winter Meeting Wrap Up

Congratulations to the NRG Oncology Members Assigned to NCI Gastrointestinal Task Forces - Rectal/Anal Cancers

FORTE Study Update - March NRG Newsletter

Coming Attractions or Recent Additions in NRG Colorectal Cancer Research: NRG-GI005

Coming Attractions or Recent Additions in NRG Colorectal Cancer Research: NRG-GI008

The NRG-GI004/SWOG1610, the COMMIT Study, may further improve outcomes in Metastatic Colorectal Cancer with deficiency of DNA repair (dMMR/MSI- H)

Project Team Member Application - CBX-12

NRG NCORP Solicits PILOT Projects for NRG NCORP Cancer Care Delivery Research (CCDR) Priorities

NRG NCORP Solicits PILOT Projects for NRG NCORP Health Disparities Research (HDR) Priorities

NRG NCORP Solicits PILOT Projects for NRG NCORP Cancer Prevention Control (CPC) Priorities

2022 Symposium & Workshop: Precision Medicine Applications in Radiation Oncology

The Scientific Session - February 2022

NRG Oncology Announces First Participant Enrolled on FORTE NRG-CC005

Dr. Miller Re-elected as Biostatistician for the NCI Uterine Task Force

RECIST 1.1 Criteria Toolkit: A Resource for Success in Clinical Trials with Solid Tumor Evaluation Requirements

NRG-CC008: A Non-Randomized Prospective Clinical Trial Comparing the Non-Inferiority of Salpingectomy to Salpingo-Oophorectomy to Reduce the Risk of Ovarian Cancer Among BRCA1 Carriers [SOROCk]

FORTE Study Updates (Feb 2022 Newsletter)

NRG Oncology Trial Results Indicate Trametinib Should Represent the New Standard of Care for Women with Recurrent Low-Grade Serous Ovarian Cancer

Trastuzumab with Chemoradiation and Surgery Does Not Improve Outcomes for Esophageal Cancer Patients, Trial Highlights Future Research Opportunities

It’s All in the DETAILS!

Moving Research Forward through Legislative Advocacy

De-intensification and Intensification Treatments for High-Risk Prostate Cancer Patients Stratified by Genomic Risk (NRG-GU009, the “PREDICT-RT” Trial)

Phase 2 Double-Blinded Trial Combining Oligometastatic Radiotherapy with Androgen Deprivation Therapy (NRG-GU011)

NRG-CC005 “FORTE” Amendment #3 is Now Active

A Message from the Chairs of NRG Oncology’s Research Strategy Committee, 2021: The Year in Review